Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Sep;40(9):2147–2151. doi: 10.1128/aac.40.9.2147

Synergy between amoxicillin and gentamicin in combination against a highly penicillin-resistant and -tolerant strain of Streptococcus pneumoniae in a mouse pneumonia model.

C Darras-Joly 1, J P Bédos 1, C Sauve 1, P Moine 1, E Vallée 1, C Carbon 1, E Azoulay-Dupuis 1
PMCID: PMC163489  PMID: 8878597

Abstract

In vivo synergy with beta-lactam antibiotics and aminoglycosides has been studied only with penicillin-susceptible Streptococcus pneumoniae strains. We evaluated the interaction between amoxicillin (AMX) and gentamicin (GEN) on the basis of in vitro checkerboard and time-kill curves and of findings in a mouse model of acute bacteremic pneumonia due to a highly penicillin-resistant and -tolerant S. pneumoniae strain of serotype 19 (penicillin and AMX MICs of 4 micrograms/ml; gentamicin MIC of 16 micrograms/ml). Checkerboard results at 18 h of incubation showed indifference. With regard to AMX alone, in vitro time-kill curves demonstrated synergy between AMX (1 microgram/ml) and GEN (16 micrograms/ml) at 5 and 8 h of incubation and for AMX (16 micrograms/ml) in combination with GEN (16 micrograms/ml) at 3, 5, and 8 h of incubation. In leukopenic mice, pulmonary killing curves after a single drug injection demonstrated that AMX (100 mg/kg of body weight) with GEN (16 mg/kg) was more effective than AMX alone (P = 10(-4). With repeated-dose treatment, a synergy was apparent at 8 h after four injections with AMX (100 mg/kg) in combination with GEN (8 or 16 mg/kg) (P < or = 0.05). The cumulative survival rate with AMX (100 mg/kg) every 8 h, combined with GEN (4 or 8 mg/kg) every 8, 12, or 24 h, was better than with AMX alone. Combined use of AMX and GEN may be a valuable therapeutic alternative for pneumococcal pneumonia due to highly penicillin-resistant S. pneumoniae strains.

Full Text

The Full Text of this article is available as a PDF (232.4 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azoulay-Dupuis E., Bedos J. P., Vallée E., Hardy D. J., Swanson R. N., Pocidalo J. J. Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis. 1991 Feb;163(2):319–324. doi: 10.1093/infdis/163.2.319. [DOI] [PubMed] [Google Scholar]
  2. Azoulay-Dupuis E., Moine P., Bedos J. P., Rieux V., Vallee E. Amoxicillin dose-effect relationship with Streptococcus pneumoniae in a mouse pneumonia model and roles of in vitro penicillin susceptibilities, autolysis, and tolerance properties of the strains. Antimicrob Agents Chemother. 1996 Apr;40(4):941–946. doi: 10.1128/aac.40.4.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Doit C. P., Bonacorsi S. P., Fremaux A. J., Sissia G., Cohen R., Geslin P. L., Bingen E. H. In vitro killing activities of antibiotics at clinically achievable concentrations in cerebrospinal fluid against penicillin-resistant Streptococcus pneumoniae isolated from children with meningitis. Antimicrob Agents Chemother. 1994 Nov;38(11):2655–2659. doi: 10.1128/aac.38.11.2655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fantin B., Carbon C. Importance of the aminoglycoside dosing regimen in the penicillin-netilmicin combination for treatment of Enterococcus faecalis-induced experimental endocarditis. Antimicrob Agents Chemother. 1990 Dec;34(12):2387–2391. doi: 10.1128/aac.34.12.2387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Fantin B., Carbon C. In vivo antibiotic synergism: contribution of animal models. Antimicrob Agents Chemother. 1992 May;36(5):907–912. doi: 10.1128/aac.36.5.907. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fantin B., Pangon B., Potel G., Vallois J. M., Caron F., Bure A., Carbon C. Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis. Antimicrob Agents Chemother. 1989 May;33(5):767–770. doi: 10.1128/aac.33.5.767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Friedland I. R., McCracken G. H., Jr Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. N Engl J Med. 1994 Aug 11;331(6):377–382. doi: 10.1056/NEJM199408113310607. [DOI] [PubMed] [Google Scholar]
  8. Friedland I. R., Paris M., Shelton S., McCracken G. H. Time-kill studies of antibiotic combinations against penicillin-resistant and -susceptible Streptococcus pneumoniae. J Antimicrob Chemother. 1994 Aug;34(2):231–237. doi: 10.1093/jac/34.2.231. [DOI] [PubMed] [Google Scholar]
  9. Frimodt-Møller N., Frølund Thomsen V. Interaction between beta-lactam antibiotics and gentamicin against Streptococcus pneumoniae in vitro and in vivo. Acta Pathol Microbiol Immunol Scand B. 1987 Oct;95(5):269–275. doi: 10.1111/j.1699-0463.1987.tb03124.x. [DOI] [PubMed] [Google Scholar]
  10. Gilbert D. N. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother. 1991 Mar;35(3):399–405. doi: 10.1128/aac.35.3.399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Greenblatt D. J., Kock-Weser J. Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975 Oct 2;293(14):702–705. doi: 10.1056/NEJM197510022931406. [DOI] [PubMed] [Google Scholar]
  12. Gross M. E., Giron K. P., Septimus J. D., Mason E. O., Jr, Musher D. M. Antimicrobial activities of beta-lactam antibiotics and gentamicin against penicillin-susceptible and penicillin-resistant pneumococci. Antimicrob Agents Chemother. 1995 May;39(5):1166–1168. doi: 10.1128/aac.39.5.1166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Haynes J., Hawkey P. M., Williams E. W. The in-vitro activity of combinations of penicillin and gentamicin against penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae. J Antimicrob Chemother. 1986 Sep;18(3):426–428. doi: 10.1093/jac/18.3.426. [DOI] [PubMed] [Google Scholar]
  14. Leggett J. E., Fantin B., Ebert S., Totsuka K., Vogelman B., Calame W., Mattie H., Craig W. A. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis. 1989 Feb;159(2):281–292. doi: 10.1093/infdis/159.2.281. [DOI] [PubMed] [Google Scholar]
  15. Moreillon P., Markiewicz Z., Nachman S., Tomasz A. Two bactericidal targets for penicillin in pneumococci: autolysis-dependent and autolysis-independent killing mechanisms. Antimicrob Agents Chemother. 1990 Jan;34(1):33–39. doi: 10.1128/aac.34.1.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pallares R., Liñares J., Vadillo M., Cabellos C., Manresa F., Viladrich P. F., Martin R., Gudiol F. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. N Engl J Med. 1995 Aug 24;333(8):474–480. doi: 10.1056/NEJM199508243330802. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES